57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

D. L. Gibbons, L. Q. Chow, D. W. Kim, S. W. Kim, T. Yeh, X. Song, H. Jiang, R. Taylor, J. Karakunnel, B. Creelan

Research output: Contribution to journal › Article › peer-review

126 Scopus citations

Fingerprint

Dive into the research topics of '57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC'. Together they form a unique fingerprint.